Cargando…
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has conseque...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000686/ https://www.ncbi.nlm.nih.gov/pubmed/21151768 http://dx.doi.org/10.3390/ph3082441 |
_version_ | 1782193560285609984 |
---|---|
author | Ellis, Leigh Pili, Roberto |
author_facet | Ellis, Leigh Pili, Roberto |
author_sort | Ellis, Leigh |
collection | PubMed |
description | Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents. |
format | Text |
id | pubmed-3000686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-30006862010-12-10 Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies Ellis, Leigh Pili, Roberto Pharmaceuticals (Basel) Review Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents. MDPI 2010-08-04 /pmc/articles/PMC3000686/ /pubmed/21151768 http://dx.doi.org/10.3390/ph3082441 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Ellis, Leigh Pili, Roberto Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
title | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
title_full | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
title_fullStr | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
title_full_unstemmed | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
title_short | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
title_sort | histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000686/ https://www.ncbi.nlm.nih.gov/pubmed/21151768 http://dx.doi.org/10.3390/ph3082441 |
work_keys_str_mv | AT ellisleigh histonedeacetylaseinhibitorsadvancingtherapeuticstrategiesinhematologicalandsolidmalignancies AT piliroberto histonedeacetylaseinhibitorsadvancingtherapeuticstrategiesinhematologicalandsolidmalignancies |